Business
InMed Pharmaceuticals Appoints Bruce S. Colwill, CPA, CA as Chief Financial Officer and Announces other Leadership Changes
InMed Pharmaceuticals Appoints Bruce S. Colwill, CPA, CA as Chief Financial Officer and An...
About this update from Infield Minerals Corp
[{"type":"text","content":"\n\n\n\nInMed Pharmaceuticals Appoints Bruce S. Colwill, CPA, CA as Chief Financial Officer and Announces other Leadership Changes\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nVANCOUVER, Aug. 2, 2019\n\n\n\nTSX:INOTCQX:IMLFF\n VANCOUVER, Aug. 2, 2019 /CNW/ - InMed Pharmaceuticals Inc. (\"InMed\" or the \"Company\") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis platform technology for the manufacturing of pharmaceutical-grade cannabinoids as well as an R&D pipeline of medications targeting diseases with high unmet medical needs, today announced the appointment of Bruce S. Colwill, CPA, CA as Chief Financial Officer, effective August 9, 2019.\n\n \n \n\n \nMr. Colwill joins InMed with over 25 years of experience in financial leadership roles. Prior to InMed, Mr. Colwill served as Chief Financial Officer of General Fusion Inc., a private clean energy company, since October 2016. Previously, Mr. Colwill was Chief Financial Officer at Entrée Resources Inc. (TSX:ETG; NYSE American:EGI) a mineral exploration company, from February 2011 to March 2016. He has also held Chief Financial Officer roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Services Inc.\n\"We are delighted to have Mr. Colwill join the InMed leadership team at a pivotal time for the Company,\" commented Eric A. Adams, President and Chief Executive Officer. \"As the CFO of multiple public and private companies, Mr. Colwill has executed a successful IPO as well as multiple equity and debt financings. His financial expertise and deep understanding of the capital markets will help ensure that InMed maintains a healthy balance sheet while continuing to execute on our broader strategic objectives.\"\n\"InMed is clearly taking a leadership position in cannabinoid-based pharmaceuticals and manufacturing technology,\" stated Mr. Colwill. \"The combination of the Company's cutting-edge platform technology, combined with its stellar leadership team, is what drew me to this exciting opportunity. I look...